Access Pharmaceuticals, a bio-pharmaceutical company engaged in using proprietary drug-delivery technologies to develop new therapies for oncology, cancer supportive care and diabetes, is presenting a poster today at the 10th Annual Diabetes Technology Meeting entitled, "Preclinical Studies with Cobalamin™ Nanoparticles for Oral Drug Delivery of Insulin." The Meeting is taking place at the Marriott Bethesda North in Bethesda, Maryland. The focus of the poster is to review ongoing developments of Access’ oral insulin formulation, which has recently been re-branded as CobOral™ after making advances with the technology.
Getting medication through the gastrointestinal tract and into the bloodstream presents a great challenge to scientists and this simple fact is that this barrier is one of the reasons that many diabetics are still injecting insulin subcutaneously. CobOral is addressing this issue and making significant strides in their development of CobOral™ as research in animal models has shown Cobalamin™-coated insulin-loaded nanoparticles given orally provide a glucose lowering effect which is slower in onset and longer in duration than injected insulin.
This is only one of the areas of unmet need that CobOral addresses. There are countless pharmaceutical active ingredients cannot be delivered by the oral route because of poor absorption of the drug in the stomach and/or degradation in the gastrointestinal tract. Access released news at the end of October that they have entered into a pre-licensing feasibility agreement with a leading bio-pharmaceutical company to develop an oral formulation of an undisclosed prostate cancer compound utilizing its proprietary vitamin B-12-based CobOral™ Drug Delivery Technology.
While most of us in this world, this author included, are not scientists and certainly have a difficult time understanding the chemistry behind biotechnological innovations and the processes behind them, it is not “smashing atoms” to understand that oral medications are far-and-away the popular mode of drug delivery. The diabetic population alone presents an enormous opportunity for Access to capitalize with successful development of this technology, without giving consideration to cancer therapies and the many other applications for which CobOral can benefit the medical community.
More information on Access Pharmaceutical, its drugs in development, its proprietary drug delivery platforms and the investment opportunity presented by ACCP can be found on the Company’s website at www.accesspharma.com.
More information on the 10th Annual Diabetes Technology Meeting at which Access is presenting can be found at www.diabetestechnology.org.
Legal Notice / Disclaimer
This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. Andrew Klips (“the author”) has based this document on information obtained from sources he believes to be reliable, but which has not been independently verified; the author makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the author only and are subject to change without notice. The author assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, the author assumes no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information provided within this Report.
The author does not own shares of Access Pharmaceuticals.
No comments:
Post a Comment